3 excellent ASX 200 growth shares experts rate as buys

Looking for ASX 200 growth shares to buy? Listed below are three that are rated as buys by experts.

Here’s why they could be top options for investors right now:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX 200 growth share to look at is Aristocrat Leisure. It is a leading global gaming content and technology company and top-tier mobile games publisher. Aristocrat offers a diverse range of products and services including electronic gaming machines, casino management systems, and freemium mobile games. The company is also looking at the real money gaming market, which could be a significant growth driver in the coming years.

Macquarie is positive on the company and has an outperform rating and $44.00 price target on its shares.

ResMed Inc. (ASX: RMD)

ResMed could be an ASX 200 growth share to buy. It is a medical device company which has a focus on the sleep treatment market. ResMed’s revenue and earnings have grown at a very strong rate over the last decade thanks to the quality of its products and its large and growing market opportunity. In respect to the latter, management estimates that there are almost one billion people with sleep apnoea globally and a little under half a billion people that suffer from chronic obstructive pulmonary disease (COPD). Thanks to its leadership position in these markets, they give ResMed a long runway for growth over the 2020s and beyond.

Goldman Sachs is bullish on ResMed and has a buy rating and $36.80 price target on its shares.

Xero Limited (ASX: XRO)

A final ASX 200 growth share that has been named as a buy is Xero. It is a provider of a cloud-based business and accounting solution. Like the others, Xero has been growing strongly over the last few years and looks well-positioned to continue this strong form for the foreseeable future. This is thanks to its international expansion, the ongoing shift to the cloud, and its burgeoning app ecosystem. The latter, which is similar to Apple’s App Store, could have significant monetisation potential in the future.

Goldman Sachs is also positive on Xero and has a buy rating and $111.00 price target on its shares.

The post 3 excellent ASX 200 growth shares experts rate as buys appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Goldman Sachs names 2 quality ASX tech shares to buy right now
• Analysts say these ASX 200 shares are buys in October
• 2 classic healthcare ASX shares priced to buy now: expert
• What’s the outlook for ASX healthcare shares in Q2?
• These 3 ASX shares have halved this year. I’d buy 2 of them: advisor

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. and Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/IAk0Hu4